Coherus Oncology (CHRS) FCF Margin (2013 - 2026)
Coherus Oncology's (CHRS) quarterly FCF Margin came in at 433.98% in Q2 2026, down 469347.0% year-over-year from N/an in Q2 2025, and up 7.71% quarter-over-quarter from 470.24% in Q1 2026.
Powered by 
Analysis
Coherus Oncology (CHRS) FCF Margin (2013 - 2026) Analysis & Trends
Coherus Oncology has disclosed FCF Margin across 13 years of filings, most recently posting 433.98% for Q2 2026.
- In Q2 2026, FCF Margin fell 469347.0% year-over-year to 433.98%; the TTM figure through Jun 2026 stood at 381.67% (down 156005.0% YoY), while the FY2025 annual figure was 786.76%, up 89.0% from the prior year.
- FCF Margin came in at 433.98% for Q2 2026 at Coherus Oncology, up from 470.24% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 6111.66% in Q1 2024 to a low of 1024.72% in Q3 2024.
- Average FCF Margin over 5 years is 439.63%, with a median of 87.79% recorded in 2022.
- Year-over-year, FCF Margin jumped 632402 bps in 2024 and sank 651362 bps in 2025.
- Over 5 years, FCF Margin stood at 220.59% in 2022, then soared by 94 bps to 14.17% in 2023, then soared by 2710 bps to 369.95% in 2024, then plunged by 160 bps to 220.36% in 2025, then plunged by 97 bps to 433.98% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 433.98% in Q2 2026, 470.24% in Q1 2026, and 220.36% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -18,629.40% |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | -433.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -433.98% |
| Mar 31, 2026 | -470.24% |
| Dec 31, 2025 | -220.36% |
| Sep 30, 2025 | -400.48% |
| Jun 30, 2025 | 4,259.49% |
| Mar 31, 2025 | -401.96% |
| Dec 31, 2024 | 369.95% |
| Sep 30, 2024 | -1,024.72% |
| Jun 30, 2024 | 968.67% |
| Mar 31, 2024 | 6,111.66% |
| Dec 31, 2023 | -14.17% |
| Sep 30, 2023 | -72.82% |
| Jun 30, 2023 | -66.45% |
| Mar 31, 2023 | -212.37% |
| Dec 31, 2022 | -220.59% |
| Sep 30, 2022 | -82.66% |
| Jun 30, 2022 | -84.65% |
| Mar 31, 2022 | -90.93% |
| Dec 31, 2021 | -71.97% |
| Sep 30, 2021 | 16.30% |